# South Australian Neonatal Medication Guidelines

# Fentanyl 100 microgram/2 mL injection © Department of Health and Wellbeing, Government of South Australia. All rights reserved

#### Note

This guideline provides advice of a general nature. This statewide guideline has been prepared to promote and facilitate standardisation and consistency of practice, using a multidisciplinary approach. The guideline is based on a review of published evidence and expert opinion.

Information in this statewide guideline is current at the time of publication.

SA Health does not accept responsibility for the quality or accuracy of material on websites linked from this site and does not sponsor, approve or endorse materials on such links.

Health practitioners in the South Australian public health sector are expected to review specific details of each patient and professionally assess the applicability of the relevant guideline to that clinical situation.

If for good clinical reasons, a decision is made to depart from the guideline, the responsible clinician must document in the patient's medical record, the decision made, by whom, and detailed reasons for the departure from the guideline.

This statewide guideline does not address all the elements of clinical practice and assumes that the individual clinicians are responsible for discussing care with consumers in an environment that is culturally appropriate and which enables respectful confidential discussion. This includes:

- The use of interpreter services where necessary,
  - Advising consumers of their choice and ensuring informed consent is obtained,
  - Providing care within scope of practice, meeting all legislative requirements and maintaining standards of professional conduct, and
    - Documenting all care in accordance with mandatory and local requirements

#### This is a High Risk Medication 🦺 An overdose can be rapidly fatal.

## **Dose and Indications**

#### **Analgesia in Self-ventilating Patients**

#### **Intravenous Bolus**

0.5 to 1 microgram/kg, a repeat dose may be given at the discretion of the treating consultant

#### Analgesia and Sedation in Ventilated Patients

#### Intravenous bolus

0.5 to 4 microgram/kg as a single dose.

Repeated as required (usually every 2 to 4 hours)

#### Intravenous Infusion

1 to 5 microgram/kg/hour (titrate to response)

#### Intubation for Ongoing Ventilation

**Intravenous Bolus** 

4 microgram/kg/dose

#### In-Out Intubation for Surfactant Therapy

#### Intravenous Bolus

1 to 2 microgram/kg/dose



INFORMAL COPY WHEN PRINTED

# Preparation and Administration

## Intravenous

#### Fentanyl 10 microgram/mL prefilled syringe\*

# \*Dilution instructions to make Fentanyl 10microgram/mL (if prefilled syringe unavailable)

Dilute 1 mL of the 100 microgram/2 mL fentanyl solution with 4 mL of compatible fluid (to a total volume of 5 mL). The resulting solution contains 10 micrograms/mL fentanyl:

Dose	1 microgram	3 microgram	5 microgram	7 microgram	9 microgram
Volume	0.1 mL	0.3 mL	0.5 mL	0.7 mL	0.9 mL

Shake well to ensure thorough mixing.

#### Administered as a push over at least 3 minutes

Rapid administration of fentanyl is associated with hypotension, bradycardia, apnoea, respiratory depression and muscle rigidity.

Discard remaining solution.

## **Continuous Intravenous Infusion**

Select the strength required based on the weight of the infant in the context of any fluid restrictions. Fentanyl Concentration Selection Tables can be found on the following pages of this guideline to assist prescribers to gauge which strength is best for the patient.

Dilute the appropriate volume of 50microgram/mL fentanyl injection using compatible fluid; and administer by continuous infusion. The dilution solution is stable at room temperature for 24 hours.

The three standard strengths available are:

- > Fentanyl 4 microgram/mL
- > Fentanyl 8 microgram/mL
- > Fentanyl 16 microgram/mL

## Formulae

#### To calculate infusion rate (mL/hr):

Rate (mL/hr) = <u>dose (microgram/kg/hour) x weight(kg)</u> Strength (microgram/mL)

To calculate the dose (microgram/kg/hour):

Dose (microgram/kg/hr) = <u>Rate (mL/hr) x Strength (microgram/mL)</u> Weight (kg)



OFFICIAL

## Fentanyl Concentration Selection Table

## Fentanyl 4 microgram/mL

#### To make 25 mL syringe:

Dilute 2 mL fentanyl (100 microgram/2 mL) with 23 mL of compatible fluid (total of 25 mL). This makes a 4 microgram/mL solution.

#### To make 50 mL syringe:

Dilute 4 mL fentanyl (100 microgram/2 mL) with 46 mL of compatible fluid (total of 50 mL). This makes a 4 microgram/mL solution.

#### Recommended for neonates weighing less than 1 kg

Rate (mL/hr)	0.2	0.3	0.4	0.5	0.6	0.7	0.8	0.9	1	Rate (mL/hr)
Weight (kg)		/	Appro	ximat	e mici	ograr	n/kg/h	our		Weight (kg)
0.5	1.6	2.4	3.2	4	4.8	5.6				0.5
1	0.8	1.2	1.6	2	2.4	2.8	3.2	3.6	4	1
1.5	0.5	0.8	1.1	1.3	1.6	1.9	2.1	2.4	2.7	1.5
2	0.4	0.6	0.8	1	1.2	1.4	1.6	1.8	2	2
2.5	0.3	0.5	0.6	0.8	1	1.1	1.3	1.4	1.6	2.5
3	0.3	0.4	0.5	0.7	0.8	0.9	1.1	1.2	1.3	3

### Fentanyl 8 microgram/mL

### To make 25 mL syringe:

Dilute 4 mL fentanyl (100 microgram/2 mL) with 21 mL of compatible fluid (total of 25 mL). This makes a 8 microgram/mL solution.

#### To make **50mL** syringe:

Dilute 8 mL fentanyl (100 microgram/2 mL) with 42 mL of compatible fluid (total of 50 mL). This makes a 8 microgram/mL solution.

Recommended for neonates weighing 1 kg to 3 kg

Rate (mL/hr)	0.2	0.3	0.4	0.5	0.6	0.7	0.8	0.9	1	Rate (mL/hr)
Weight (kg)		/	Appro	ximat	e micr	ograr	n/kg/h	our		Weight (kg)
1	1.6	2.4	3.2	4	4.8	5.6				1
1.5	1.1	1.6	2.1	2.7	3.2	3.7	4.3	4.8	5.3	1.5
2	0.8	1.2	1.6	2	2.4	2.8	3.2	3.6	4	2
2.5		1	1.3	1.6	1.9	2.2	2.6	2.9	3.2	2.5
3		0.8	1.1	1.3	1.6	1.9	2.1	2.4	2.7	3
3.5			0.9	1.1	1.4	1.6	1.8	2.1	2.3	3.5



## Fentanyl 16 microgram/mL

#### To make 25 mL syringe:

Dilute 8 mL fentanyl (100 microgram/2 mL) with 17 mL of compatible fluid (total of 25 mL). This makes a 16 microgram/mL solution.

#### To make 50 mL syringe:

Dilute 16 mL fentanyl (100 microgram/2 mL) with 34 mL of compatible fluid (total of 50 mL). This makes a 16 microgram/mL solution.

Recommended for neonates greater than 3 kg

Rate (mL/hr)	0.2	0.3	0.4	0.5	0.6	0.7	0.8	0.9	1	Rate (mL/hr)
Weight (kg)		/	Appro	ximate	e micr	ograr	n/kg/h	our		Weight (kg)
2	1.6	2.4	3.2	4	4.8					2
2.5	1.3	1.9	2.6	3.2	3.8	4.5	5.1			2.5
3	1.1	1.6	2.1	2.7	3.2	3.7	4.3	4.8	5.3	3
3.5	0.9	1.4	1.8	2.3	2.7	3.2	3.7	4.1	4.6	3.5
4	0.8	1.2	1.6	2	2.4	2.8	3.2	3.6	4	4
4.5		1.1	1.4	1.8	2.1	2.5	2.8	3.2	3.5	4.5
5		1	1.3	1.6	1.9	2.2	2.6	2.9	3.2	5

# **Compatible Fluids**

Glucose 5%, sodium chloride 0.9%

Glucose 10% (stability data not available, however accepted in clinical practice)

# Adverse Effects

#### Common

Laryngospasm, respiratory depression, miosis, urinary retention, constipation, rash, erythema and bradycardia.

May have a lower incidence of vomiting and constipation than other opioids

#### Infrequent

Chest wall rigidity, bronchospasm, tremor, hypothermia, tachycardia, hypertension, ureteric or biliary spasm, urticaria, muscle rigidity and myoclonus

#### Rare

Syndrome of inappropriate antidiuretic hormone hypersecretion (SIADH) and seizures



# Monitoring

- > Continuous cardiorespiratory monitoring and SpO<sub>2</sub>
- > Close observation of the neonate for at least 30 minutes is required to assess for respiratory depression
- > Pain is best monitored by using a pain score
- > Urine output (continuous infusion) to monitor for urinary retention

# **Practice Points**

- Physiological dependence and tolerance may occur with prolonged use (i.e. greater than 5 days of continuous dosing)
- > Use with CAUTION in neonates:
  - not receiving assisted ventilation
  - with high intracranial pressure or convulsions
  - with urinary retention
  - with bradyarrhythmias or hypotension
- > Fentanyl has a shorter half-life and greater cardiovascular stability than other opiates
- > If fentanyl is used in conjunction with other sedative medications (e.g. midazolam) the dose of each must be reduced
- > Naloxone should be available for reversal of opioid adverse effects.

## Document Ownership & History

Developed by:	SA Maternal, Neonatal & Gynaecology Community of Practice							
Contact:	Health.NeoMed@sa.gov.au							
Endorsed by:	Safety and Quality, Clinical Support and Improvement, SA Health							
Next review due:	18/10/2028							
ISBN number:	978-1-76083-591-0							
CGSQ reference:	NMG 049							
Policy history:	Is this a new policy (V1)? <b>N</b>							
	Does this policy amend or update and existing policy? Y							
	If so, which version? V4.0							
	Does this policy replace another policy with a different title? <b>N</b>							
	If so, which policy (title)?							

Approval Date	Version	Who approved New/Revised Version	Reason for Change
18/10/2023	V5.0	Domain Custodian, Safety and Quality	Updates to dose and indications, prep and administration, compatible fluids, adverse effects, and monitoring
11/2017	V4.0	SA Health Safety and Quality Strategic Governance Committee	Addition of pre-filled syringes
09/2016	V3.0	SA Health Safety and Quality Strategic Governance Committee	Review and update
01/2015	V2.0	SA Health Safety and Quality Strategic Governance Committee	High Risk notification included
11/2012	V1.0	SA Maternal & Neonatal Clinical Network	Original SA Maternal & Neonatal Clinical Network approved version.

